

FY 2008 -09



DELIVERING
AFFORDABLE
INNOVATION



Disclaimer

Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our company, nor our directors, nor any of their respective affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.

Corporate Developments

AxiCorp wins German AOK tender for Metformin

- AxiCorp selected as the AOK tender supplier for Metformin in Germany over the next 2 years

DCGI marketing approval for Insulin Glargine

- The trial data, for a non-inferiority Phase III Clinical trial for Glargine, a basal Insulin analog has been approved by DCGI for marketing.

Corporate Developments

BIOMAb EGFR™ voted “Product of the Year”

- Received the Bio-Spectrum Asia Pacific Product of the Year Award 2008.



Dr Arun Chandavarkar of Biocon receives Product of the Year Award from Mr S Iswaran

BIOMAb-EGFR:
An affordable
application



BIOMAb-EGFR, a therapeutic monoclonal antibody-based drug for treating solid tumors of epithelial origin, clinically developed in India, is the first by an Indian company

**BioSpectrum Asia Pacific
Product of the Year
Award 2008**

BIOMAb EGFR

Corporate Developments

Biocon wins award for Best Listed Biotechnology Company in Asia Pacific

Biocon won the 2009 BioSingapore Asia Pacific Biotechnology Award as the 'Best Listed Company' based on significant market capital, sound business model and excellent management team.



Corporate Developments

Syngene and DuPont Crop Protection Forge Alliance

Already a research service provider to DuPont Crop Protection in discovery chemistry and biology, Syngene will now provide integrated research services through its "one box" model.


Syngene partners with Innate Pharmaceuticals for the Development of Type III Virulence Blockers:

Novel treatment strategies for diarrhea

Corporate Developments

Biocon Bristol Myers Squibb Research Center (BBRC) inaugurated

Syngene and Bristol-Myers Squibb Company opened a fully dedicated research and development facility for Bristol-Myers Squibb in Biocon Park



Corporate Developments


Clinigene enrolls patients for Phase III Clinical Trials for IN105 (Oral Insulin)

A Phase III pivotal study for oral insulin (IN-105) has been initiated across various hospitals in India, consequently patient enrollment is in progress.

Clinigene completes patient recruitment for Phase IIb trials for T1h for RA & Psoriasis

First study- Multicentre Phase II dose ranging study, to evaluate the safety & efficacy of T1h along with standard of care in patients with severe **methotrexate** resistant Rheumatoid Arthritis.

Second study - Phase II dose ranging study in patients with active moderate to severe Psoriasis. T1h is being studied in various doses and frequency along with the standard of care to confirm its efficacy and safety.




Financial Highlights

Sales Breakup – FY 09 Vs FY 08



Rs Crs




Financial Performance – FY 09 Vs FY 08



Rs Crs

	FY09	%	FY 08	%
Revenues	1,673		1,090	
E B I D T A	388	31	335	31
P B T	260	16	231	21
P A T (Excl Exceptional)	240	14	225	21
Exceptional (MTM / Enzymes)	(147)		239	
P A T	93		464	

DELIVERING
AFFORDABLE
INNOVATION



THANK
YOU